GI Disorders - Inflammatory, Lower GI

MODULE 9: GI DISORDERS

11: Inflammatory, Lower GI
NURS 317

INFLAMMATORY BOWEL DISEASE (IBD)

Overview

  • Definition: IBD refers to chronic inflammatory disorders of the gastrointestinal (GI) tract.

  • Affected Area: The entire GI tract is susceptible.

  • Major Types: There are two major types of IBD:

    • Crohn's Disease: Characterized by transmural granulomatous inflammation.

    • Ulcerative Colitis (UC): Also known as vicerative colitis (VCI).

  • Common Features:

    • Both types involve relapsing-remitting flares leading to full-thickness inflammation.

    • Both increase the risk of colon cancer over time.

Clinical Features

  • Symptoms:

    • Abdominal pain

    • Diarrhea

    • Weight loss

    • Fluid/electrolyte imbalance

    • Low-grade fever

    • Fatigue

  • **Complications of IBD: **

    • Fistulas: Pathological tunneling that can lead to perforation.

    • Abscesses: Pockets of pus.

    • Obstruction: Blockage can occur in the intestines.

Diagnostics

  • Procedures:

    • Sigmoidoscopy

    • Stool culture

    • CT scan


ULCERATIVE COLITIS (UC)

Pathophysiology

  • Type: Mucosal/submucosal inflammation.

  • Pattern of Spread: Continuous spread starting from the rectum.

Clinical Features

  • Symptoms:

    • Bloody diarrhea mixed with mucus

    • Urgency to defecate

    • Left lower quadrant (LLQ) cramps

  • Complications:

    • Toxic megacolon: Severe inflammation causes the colon to fail to push contents forward, leading to colon distention.

    • Colorectal cancer.

    • Tenesmus: Severe discomfort in the lower abdomen, feeling of needing to pass stool without relief.

Diagnostics

  • Procedures:

    • Colonoscopy with biopsy to examine mucosal and submucosal layers.

    • Stool cultures are also performed.

  • Result: Provide immediate indication of pathology in the colon.

Treatment Goals

  • Primary Goal: To increase remission time and reduce complications.


PHARMACOLOGY IN IBD

Goals of Pharmacological Management

  • Medications Used for IBD:

    • 5-ASA Prototype: Sulfasalazine (Azulfidine)

    • Objective: Induce and maintain remission. (No cure)

    • Use in: Maintenance of remission in UC. Cannot cure chronic IBD.

    • Drug Classes:

    • 5-ASA drugs (Amino salicylates)

    • Biologics (TNF inhibitors)

    • Corticosteroids

    • DMARDs (Disease-modifying antirheumatic drugs)

    • Immunosuppressants

Indications

  • Mild to moderate UC; off-label for chronic forms.


NURSING CONSIDERATIONS

Monitoring and Education

  • Monitoring: Routine checks on CBC and folate levels.

  • Patient Education:

    • Adverse effects: Nausea, vomiting, diarrhea, photosensitivity, headaches.

    • Guidelines for preventing dehydration, sun protection strategies.

    • Warning about temporary infertility risk during treatment (particularly for males) with education on returning fertility.

Risks and Contraindications

  • 5-ASA Options:

    • Mesalamine

    • Balsalazide

  • Contraindications:

    • Sulfa or aspirin allergy

    • Urinary obstruction

    • Anemia or folate disorders

    • Hepatic impairment

Escalation Therapy

  • Prototype Medications:

    • TNF Inhibitor Prototype: Adalimumab (Humira)

    • Integrin Blocker Prototype: Vedolizumab

Risks of Drug Therapy

  • Serious infections (e.g., TB reactivation)

  • Immunosuppressants: Azathioprine (and risks for malignancies)

  • Nursing Screening: For TB/hepatitis before starting immunosuppressants.

Monitoring

  • Monitor infusion reactions and signs of hepatotoxicity.


LOWER GI DISORDERS

Diverticulosis vs. Diverticulitis

  • Diverticulosis: Presence of outpouchings, which are often asymptomatic.

  • Diverticulitis: Occurs when non-digested food particles become trapped in diverticula (e.g., popcorn kernels, seeds).

    • Symptoms of Diverticulitis: Abdominal pain, fever.

  • Complications:

    • Perforation, abscesses, obstruction.

  • Management of Diverticulitis:

    • NPO (nothing by mouth) order, IV antibiotics, surgery if complicated.


APPENDICITIS

Cause
  • Fecalith obstruction is the most common etiology.

Symptoms
  • RLQ (right lower quadrant) pain.

  • Rebound tenderness, fever, and elevated WBC (white blood cells).

Risk of Untreated Appendicitis
  • Perforation leading to peritonitis.

Management
  • Appendectomy is the surgical intervention required.


INTESTINAL OBSTRUCTION

Types
  • Mechanical Obstruction: Caused by adhesions or hernias.

  • Paralytic Ileus: Neurogenic or post-operative cessation of bowel function.

Symptoms
  • Colicky abdominal pain, no bowel movement, and resulting distension.

Management
  • First-line Treatment: Bowel rest with NPO order. Correct underlying issues, not just decompression. Surgery may be necessary to relieve strangulation.


PARALYTIC ILEUS

Background

  • Definition: A type of bowel obstruction where food or drink does not pass through the intestines due to the loss of peristalsis.

Causes

  • Stress response from abdominal or pelvic surgery.

  • Infection or inflammation from conditions such as:

    • Gastroenteritis

    • Pancreatitis

    • Peritonitis

    • Diverticulitis

  • Electrolyte imbalances.

  • Vascular/neural impairment.

  • Use of certain medications (e.g., opioids).

Treatment

  • Focus on relieving symptoms and addressing the underlying cause.

  • Management includes bowel rest, IV fluid therapy (if NPO), total parenteral nutrition (TPN), and possibly using a nasogastric tube for decompression. Surgery may be indicated for extended cases.


SYMPTOM SYNDROMES IN GI DISORDERS

Nausea and Vomiting

Centers Involved
  • Vomiting Center: Located in the medulla oblongata, integrated with several triggers and signals from the gastrointestinal tract, vestibular systems, toxins, and chemotherapy drugs.

Complications of Nausea and Vomiting
  • Risks of dehydration, motion sickness, food poisoning, chemical toxicity, bowel obstruction.

Antiemetic Pharmacology
  • 5-HT3 Antagonist Prototype: Ondansetron (Zofran)

    • MOA: Blocks serotonin receptors in the gut, reducing nausea and vomiting.

    • Common Uses: Nausea and vomiting; particularly severe cases during pregnancy.

    • Adverse Effects: Headaches, constipation, QT prolongation, serotonin syndrome, tinnitus.


DOPAMINE ANTAGONISTS

D2 Antagonist Prototype

  • Example: Prochlorperazine (Compazine)

    • Class: Dopamine (D2) receptor antagonists, phenothiazine class.

    • MOA: Blocks dopamine receptors in the chemoreceptor trigger zone, suppressing nausea and vomiting.

Adverse Effects and Contraindications

  • Common Side Effects: Sedation, dizziness, hypotension, anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision).

  • Contraindications: Comatose patients, children under 2 years, moderate nausea/vomiting post-op, narrow-angle glaucoma.

Nursing Considerations

  • Monitor for extrapyramidal symptoms (EPS) and educate on reporting red flags such as tardive dyskinesia, akathisia, and other abnormal movements.


DIARRHEA

Pathophysiology

  • Acute Diarrhea: Usually infectious (can be watery or bloody).

  • Chronic Diarrhea: Associated with IBD, irritable bowel syndrome (IBS), malabsorption syndromes, endocrine disorders.

Complications of Diarrhea

  • Risks include dehydration, hypokalemic metabolic acidosis due to excessive bicarbonate loss.

Antidiarrheal Prototype
  • Example: Diphenoxylate/Atropine (Lomotil)

    • Classification: Opioid antagonist with atropine added to discourage abuse.

    • MOA: Acts on intestinal smooth muscle to slow peristalsis, enhancing fluid absorption and reducing stool frequency.

Nursing Considerations
  • Indications: Moderate to severe diarrhea of non-infectious origin.

  • Adverse Effects: CNS depression effects like dizziness and drowsiness, anticholinergic effects such as dry mouth.

  • Contraindications: Risk of exacerbation in C. diff infections. Monitor for electrolytic imbalances.


CONSTIPATION

Causes

  • Factors contributing include low fiber intake, low fluid intake, inactivity, certain medication use (especially opioids and anticholinergics).

Complications

  • Severe complications include fecal impaction, which can lead to mechanical obstruction, ileus, and overall obstruction.

Laxative Pharmacology and Management
  • Nutritional Measures: Increase dietary fiber.

  • Prophylactic Use in Opioid-Induced Constipation (OIC): Start with stool softeners like docusate or stimulant laxatives such as senna or bisacodyl.

  • Contraindications: Avoid giving laxatives if signs of obstruction or absent bowel sounds are present.

  • Teaching Points for Patients: Importance of adequate hydration, fiber intake, and a routine bowel regimen.


SUMMARY

  • Understanding these GI disorders, including their pathophysiology, clinical features, diagnostics, and treatment options, is crucial for effective nursing practice and patient care. Regular monitoring and patient education are essential components of the nursing role in managing these conditions.